Renal cell carcinoma articles from across Nature Portfolio

In this Perspective, the authors provide an overview of the most promising deregulated non-coding RNAs in clear-cell renal cell carcinoma, discussing the role of different classes of non-coding RNAs in clear-cell renal cell carcinoma development and progression. Future perspectives and challenges associated with the translation of these markers into clinical practice are also discussed.

Studying changes in the metabolic properties of kidney cancer in patients reveals an increased need for mitochondrial metabolism as tumors metastasize from the kidney to distant organs.

A machine learning-derived gene signature that integrates germline HLA characteristics with a distinct spatial community of CD8⁺ T cells and tumor-associated macrophages showing immunogenic interactions is predictive of the response to immunotherapy in patients with advanced kidney cancer.

In the KEYNOTE-564 trial, patients with resected clear cell renal cell carcinoma at a high risk of relapse experienced disease-free survival and especially overall survival benefits following treatment with pembrolizumab, which in turn was established as the novel standard adjuvant therapy for these patients. Accurate patient selection is crucial. Managing post-pembrolizumab recurrence is challenging owing to limited evidence for guiding therapeutic decisions based on clinical features.